FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
3. Date of Earliest Transaction
(Month/Day/Year) 01/27/2023 | ||||||||||||||||||||||||||
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 01/27/2023 | M | 388 | A | (1) | 1,519(2) | I | Wife | ||
Common Stock | 01/27/2023 | S | 141(3) | D | $7.49 | 1,378 | I | Wife | ||
Common Stock | 01/27/2023 | M | 3,883 | A | (1) | 85,973(4) | D | |||
Common Stock | 01/27/2023 | S | 1,382(3) | D | $7.49 | 84,591 | D(5) | |||
Common Stock | 19,394 | I | See Footnote(6) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Restricted Stock Units | (1) | 01/27/2023 | M | 388 | (7) | (7) | Common Stock | 388 | $0.00 | 1,165 | I | Wife | |||
Restricted Stock Units | (1) | 01/27/2023 | M | 3,883 | (8) | (8) | Common Stock | 3,883 | $0.00 | 11,650 | D |
Explanation of Responses: |
1. Restricted stock units convert into common stock on a one-for-one basis. |
2. Includes 1,462 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on November 30, 2022. |
3. This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). |
4. Includes 490 shares of common stock and 1,462 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2022 and November 30, 2022, respectively. |
5. Represents 81,931 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. |
6. Represents 19,394 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017. |
7. On January 27, 2022 (the "Grant Date"), Ms. Ganot was granted 1,553 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. |
8. On the Grant Date, the reporting person was granted 15,533 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. |
Remarks: |
/s/ by David Tyrone Howton as attorney-in-fact for Ilan Ganot | 01/31/2023 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |